Rosai-Dorfman-Destombes disease
Revision as of 12:25, 15 July 2024 by Warner-admin (talk | contribs) (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''")
Section editor | |
---|---|
Gaurav Goyal, MD UAB Birmingham, AL, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
Consensus guidelines
- 2018: Abla et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease link to PMC article PubMed
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Histiocytic Neoplasms.
All lines of therapy
Cobimetinib monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Diamond et al. 2019 (MSK 15-216) | 2016 to not reported | Phase 2, fewer than 20 pts in this arm (RT) |
Note: there were N=2 patients with this type of histiocytosis.
References
- MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02649972